Cargando…
Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior
BACKGROUND: Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) from young healthy donors are immunoprivileged and their clinical application for regenerative medicine is under evaluation. However, data from preclinical and initial clinical trials indicate that allogeneic MSCs after transpl...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930635/ https://www.ncbi.nlm.nih.gov/pubmed/29720263 http://dx.doi.org/10.1186/s13287-018-0867-4 |
_version_ | 1783319518188142592 |
---|---|
author | Sareen, Niketa Sequiera, Glen Lester Chaudhary, Rakesh Abu-El-Rub, Ejlal Chowdhury, Subir Roy Sharma, Vikram Surendran, Arun Moudgil, Meenal Fernyhough, Paul Ravandi, Amir Dhingra, Sanjiv |
author_facet | Sareen, Niketa Sequiera, Glen Lester Chaudhary, Rakesh Abu-El-Rub, Ejlal Chowdhury, Subir Roy Sharma, Vikram Surendran, Arun Moudgil, Meenal Fernyhough, Paul Ravandi, Amir Dhingra, Sanjiv |
author_sort | Sareen, Niketa |
collection | PubMed |
description | BACKGROUND: Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) from young healthy donors are immunoprivileged and their clinical application for regenerative medicine is under evaluation. However, data from preclinical and initial clinical trials indicate that allogeneic MSCs after transplantation provoke a host immune response and are rejected. In the current study, we evaluated the effect of an increase in passage number in cell culture on immunoprivilege of the MSCs. Since only limited numbers of MSCs can be sourced at a time from a donor, it is imperative to expand them in culture to meet the necessary numbers required for cell therapy. Presently, the most commonly used passages for transplantation include passages (P)3–7. Therefore, in this study we included clinically relevant passages, i.e., P3, P5, and P7, for evaluation. METHODS: The immunoprivilege of MSCs was assessed with the mixed leukocyte reaction assay, where rat MSCs were cocultured with peripheral blood leukocytes for 72 h. Leukocyte-mediated cytotoxicity, apoptosis (Bax/Bcl-xl ratio), leukocyte proliferation, and alterations in cellular bioenergetics in MSCs were assessed after the coculture. Furthermore, the expression of various oxidized phospholipids (oxidized phosphatidylcholine (ox-PC)) was analyzed in MSCs using a lipidomic platform. To determine if the ox-PCs were acting in tandem with downstream intracellular protein alterations, we performed proteome analysis using a liquid chromatography/mass spectrometry (LC/MS) proteomic platform. RESULTS: Our data demonstrate that MSCs were immunoprivileged at all three passages since coculture with leukocytes did not affect the survival of MSCs at P3, P5, and P7. We also found that, with an increase in the passage number of MSCs, leukocytes did not cause any significant effect on cellular bioenergetics (basal respiration rate, spare respiratory capacity, maximal respiration, and coupling efficiency). Interestingly, in our omics data, we detected alterations in some of the ox-PCs and proteins in MSCs at different passages; however, these changes were not significant enough to affect their immunoprivilege. CONCLUSIONS: The outcome of this study demonstrates that an increase in passage number (from P3 to P7) in the cell culture does not have any significant effect on the immunoprivilege of MSCs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-018-0867-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5930635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59306352018-05-09 Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior Sareen, Niketa Sequiera, Glen Lester Chaudhary, Rakesh Abu-El-Rub, Ejlal Chowdhury, Subir Roy Sharma, Vikram Surendran, Arun Moudgil, Meenal Fernyhough, Paul Ravandi, Amir Dhingra, Sanjiv Stem Cell Res Ther Research BACKGROUND: Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) from young healthy donors are immunoprivileged and their clinical application for regenerative medicine is under evaluation. However, data from preclinical and initial clinical trials indicate that allogeneic MSCs after transplantation provoke a host immune response and are rejected. In the current study, we evaluated the effect of an increase in passage number in cell culture on immunoprivilege of the MSCs. Since only limited numbers of MSCs can be sourced at a time from a donor, it is imperative to expand them in culture to meet the necessary numbers required for cell therapy. Presently, the most commonly used passages for transplantation include passages (P)3–7. Therefore, in this study we included clinically relevant passages, i.e., P3, P5, and P7, for evaluation. METHODS: The immunoprivilege of MSCs was assessed with the mixed leukocyte reaction assay, where rat MSCs were cocultured with peripheral blood leukocytes for 72 h. Leukocyte-mediated cytotoxicity, apoptosis (Bax/Bcl-xl ratio), leukocyte proliferation, and alterations in cellular bioenergetics in MSCs were assessed after the coculture. Furthermore, the expression of various oxidized phospholipids (oxidized phosphatidylcholine (ox-PC)) was analyzed in MSCs using a lipidomic platform. To determine if the ox-PCs were acting in tandem with downstream intracellular protein alterations, we performed proteome analysis using a liquid chromatography/mass spectrometry (LC/MS) proteomic platform. RESULTS: Our data demonstrate that MSCs were immunoprivileged at all three passages since coculture with leukocytes did not affect the survival of MSCs at P3, P5, and P7. We also found that, with an increase in the passage number of MSCs, leukocytes did not cause any significant effect on cellular bioenergetics (basal respiration rate, spare respiratory capacity, maximal respiration, and coupling efficiency). Interestingly, in our omics data, we detected alterations in some of the ox-PCs and proteins in MSCs at different passages; however, these changes were not significant enough to affect their immunoprivilege. CONCLUSIONS: The outcome of this study demonstrates that an increase in passage number (from P3 to P7) in the cell culture does not have any significant effect on the immunoprivilege of MSCs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13287-018-0867-4) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-02 /pmc/articles/PMC5930635/ /pubmed/29720263 http://dx.doi.org/10.1186/s13287-018-0867-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sareen, Niketa Sequiera, Glen Lester Chaudhary, Rakesh Abu-El-Rub, Ejlal Chowdhury, Subir Roy Sharma, Vikram Surendran, Arun Moudgil, Meenal Fernyhough, Paul Ravandi, Amir Dhingra, Sanjiv Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior |
title | Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior |
title_full | Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior |
title_fullStr | Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior |
title_full_unstemmed | Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior |
title_short | Early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior |
title_sort | early passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930635/ https://www.ncbi.nlm.nih.gov/pubmed/29720263 http://dx.doi.org/10.1186/s13287-018-0867-4 |
work_keys_str_mv | AT sareenniketa earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT sequieraglenlester earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT chaudharyrakesh earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT abuelrubejlal earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT chowdhurysubirroy earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT sharmavikram earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT surendranarun earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT moudgilmeenal earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT fernyhoughpaul earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT ravandiamir earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior AT dhingrasanjiv earlypassagingofmesenchymalstemcellsdoesnotinstigatesignificantmodificationsintheirimmunologicalbehavior |